VRDN Q2 2025 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75,000+4.2% YoY

Gross Profit

$75,000100.0% margin

Operating Income

-$107M-142356.0% margin

Net Income

-$101M-134313.3% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$75M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$582M

Total Liabilities

$67M

Stockholders' Equity

$515M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75,000	$72,000	+4.2%
Gross Profit	$75,000	$72,000	+4.2%
Operating Income	-$107M	-$72M	-47.9%
Net Income	-$101M	-$65M	-55.0%

Revenue Segments

Collaboration Revenue

$100,000100%